Goldman Sachs Initiates Coverage On Adaptive Biotechnologies with Buy Rating, Announces Price Target of $35

Benzinga Newsdesk www.benzinga.com Neutral 53.6%

Neg 0% Neu 53.6% Pos 0%

Goldman Sachs analyst Evie Koslosky initiates coverage on Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy rating and announces Price Target of $35.